Clinical Trial Update: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for DT2219ARL in relapsed or refractory CD19+/CD22+ B-lineage leukemia or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• DT2219ARL

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED